Cancer Research

The Cancer Research theme encompasses companies advancing the prevention, detection, and treatment of malignancies across the oncology pipeline. Core tracks include oncology drug discovery and clinical development, immuno-oncology and cell/gene therapies, precision medicine with biomarkers and companion diagnostics, genomics and liquid biopsy, plus research tools, CROs, and enabling platforms.The sector's total market cap is 1071.29 billion USD, with a 24h change of +0.38%. Among 6 constituents, 4 are up (66.67%) and 2 are down (33.33%). The top gainer is Gilead Sciences Inc (GILD), with a 24h increase of +0.89%.Leaders extend a modest advance on healthy breadth. Prioritize high-conviction names with near-term clinical catalysts; add on pullbacks and manage risk around trial and regulatory events.